Results 281 to 290 of about 144,142 (399)
Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options
ABSTRACT Atypical chronic myeloid leukemia (aCML) is a rare form of myelodysplastic (MDS)/myeloproliferative neoplasm (MPN) overlap disorder characterized by neutrophilic leukocytosis with circulating immature myeloid cells (IMC), frequent hepatosplenomegaly, and poor prognosis with high rates of leukemic transformation.
Alessandra Iurlo +3 more
wiley +1 more source
A Case of Drug-Induced Lung Injury With Systemic Features Resembling DRESS Caused by Saiko-Ka-Ryukotsu-Borei-To and Goreisan. [PDF]
Ogata T +5 more
europepmc +1 more source
Clinical, radiological, and laboratory assessment of pulmonary eosinophilia syndrome: a case control study in Saudi Arabia. [PDF]
Ahmed MI, Ali SAM, Ahmed RI.
europepmc +1 more source
Allopurinol‐Induced Lymphadenopathy: A Case Report
ACR Open Rheumatology, Volume 7, Issue 12, December 2025.
Mikako Harata, Aparna Das
wiley +1 more source
An infant with drug reaction with eosinophilia and systemic symptoms caused by phenobarbital and amoxicillin: A case report. [PDF]
Matsumoto Y, Fujita M, Inuo C, Inuo C.
europepmc +1 more source
ABSTRACT Chemokine receptor type 5 (CCR5) is upregulated in the livers of patients with metabolic dysfunction–associated steatohepatitis (MASH). Leronlimab, a humanised IgG4κ monoclonal antibody, directly binds the extracellular domains of CCR5, modulates downstream signalling and potentially can slow, reverse or prevent fibrosis. The aim of this study
Melissa Palmer +10 more
wiley +1 more source
Eosinophil-associated disease after SARS-CoV-2 infection or vaccination: EGPA and related entities. [PDF]
Alrehaili GA, Keogh KA, Baqir M.
europepmc +1 more source
ABSTRACT Objective This study aimed to evaluate the clinical remission rate and changes in medication use in patients with eosinophilic chronic rhinosinusitis (ECRS) treated with dupilumab for > 2 years. Methods This retrospective study included 19 patients with ECRS who received dupilumab therapy for > 2 years. The nasal polyp, Lund–Mackay on sinus CT,
Seiichiro Kamimura +4 more
wiley +1 more source
ABSTRACT The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell ...
Anqi Lin +8 more
wiley +1 more source

